Pharmaron Beijing Co Ltd

Price Chart

Risk-Adjusted Performance

Also Listed On

Pharmaron Beijing Co Ltd (3759) Price Performance

Pharmaron Beijing Co Ltd (3759) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD18.40, down 0.43% from the previous close.

Over the past year, 3759 has traded between a low of HKD11.39 and a high of HKD29.90. The stock has gained 17.3% over this period. It is currently 38.5% below its 52-week high.

Pharmaron Beijing Co Ltd has a market capitalization of $57.33B, with a price-to-earnings ratio of 18.14 and a dividend yield of 0.83%.

About Pharmaron Beijing Co Ltd

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.